Peter Altman Purchases 48,000 Shares of BioCardia (NASDAQ:BCDA) Stock

BioCardia, Inc. (NASDAQ:BCDA) CEO Peter Altman purchased 48,000 shares of the business’s stock in a transaction on Friday, September 19th. The stock was acquired at an average price of $1.25 per share, for a total transaction of $60,000.00. Following the completion of the purchase, the chief executive officer owned 216,762 shares of the company’s stock, valued at $270,952.50. This represents a 28.44% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Peter Altman also recently made the following trade(s):

• On Friday, August 22nd, Peter Altman purchased 700 shares of BioCardia stock. The stock was acquired at an average price of $1.83 per share, for a total transaction of $1,281.00.
• On Wednesday, August 13th, Peter Altman purchased 100 shares of BioCardia stock. The stock was acquired at an average price of $1.83 per share, for a total transaction of $183.00.
• On Tuesday, August 12th, Peter Altman purchased 400 shares of BioCardia stock. The stock was acquired at an average price of $1.75 per share, for a total transaction of $700.00.
• On Monday, August 11th, Peter Altman acquired 1,700 shares of BioCardia stock. The shares were purchased at an average cost of $1.76 per share, for a total transaction of $2,992.00.
• On Monday, June 30th, Peter Altman acquired 24,096 shares of BioCardia stock. The shares were purchased at an average cost of $2.08 per share, for a total transaction of $50,119.68.

BioCardia Stock Performance

Shares of BCDA stock opened at $1.48 on Thursday. The stock’s 50-day moving average is $1.94 and its two-hundred day moving average is $2.16. The firm has a market cap of $8.60 million, a price-to-earnings ratio of -0.80 and a beta of 0.85. BioCardia, Inc. has a 1 year low of $1.00 and a 1 year high of $3.20.

BioCardia (NASDAQ:BCDA) last issued its quarterly earnings data on Monday, August 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.50) by $0.10. As a group, research analysts predict that BioCardia, Inc. will post -3.52 EPS for the current year.

Hedge Funds Weigh In On BioCardia

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. CM Management LLC grew its holdings in shares of BioCardia by 200.0% during the first quarter. CM Management LLC now owns 75,000 shares of the company’s stock worth $190,000 after buying an additional 50,000 shares during the last quarter. Brown Advisory Inc. purchased a new position in shares of BioCardia during the first quarter worth about $90,000. Finally, Cetera Investment Advisers purchased a new position in shares of BioCardia during the second quarter worth about $40,000. Hedge funds and other institutional investors own 20.57% of the company’s stock.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and set a $25.00 price objective on shares of BioCardia in a report on Monday. One analyst has rated the stock with a Strong Buy rating and one has assigned a Buy rating to the stock. According to data from MarketBeat.com, BioCardia has an average rating of “Strong Buy” and a consensus price target of $25.00.

BioCardia Company Profile

BioCardia, Inc, a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. Its lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.